Document is current
Any future updates will be listed below
-
Authors
Chowdhury, Sayan Mullick
Bhatta, Subodh
Voorhees, Timothy J.
Annunzio, Kaitlin
Bond, David A.
Sawalha, Yazeed
Sigmund, Audrey
Hanel, Walter
Sehgal, Lalit
Alinari, Lapo
Baiocchi, Robert
Maddocks, Kami
Christian, Beth
Jones, Dan
Epperla, Narendranath
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 30 December 2024
First Online: 5 January 2025
Declarations
:
: The study was approved by the institutional review board and was conducted in compliance with the Declaration of Helsinki.
: NE: Research funding: Beigene, Lilly, and Incyte; Speakers Bureau for Beigene and Genentech; Ad boards for ADC Therapeutics, Lilly, and Ipsen; Honorarium from Novartis. TJV: Advisory Board: Genmab/AbbVie, ADC Therapeutics. Consultancy: Novartis, Recordati, Genmab. Research Funding: Kite, Viracta, Incyte/Morphosys, Genmab/AbbVie, Recordati. DAB: Advisory Board: Novartis, Nurix Therapeutics, ADC Therapeutics. Research Funding: Novartis, Kite/Gilead, Accutar, Nurix Therapeutics, Incyte, GenMab, BeiGene. Astra Zeneca.BC Advisory Board: Ipsen, AstraZeneca; Research Support: Genentech, Acerta, Millenium, Kite, Bristol Myers Squibb KM: Consulting: AbbVie, ADC Therapeutics, AstraZeneca/Acerta, Beigene, BMS, Caribou, Genentech, Genmab, Gilead/KITE, Incyte, Janssen, Lilly, Morphosys, Pharmacyclics.
